Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Talaris Therapeutics (TALS) News Today

Talaris Therapeutics logo
Tourmaline Bio, Inc. (TRML)
Longitude Venture Partners III, L.P.'s Net Worth
Talaris Therapeutics, Inc. stock logo
RA Capital Management L.P. Takes Position in Talaris Therapeutics, Inc. (NASDAQ:TALS)
RA Capital Management L.P. acquired a new stake in shares of Talaris Therapeutics, Inc. (NASDAQ:TALS - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 2,333,175 shares of the company's stock, valu
Talaris Therapeutics, Inc. stock logo
Acadian Asset Management LLC Raises Holdings in Talaris Therapeutics, Inc. (NASDAQ:TALS)
Acadian Asset Management LLC lifted its stake in Talaris Therapeutics, Inc. (NASDAQ:TALS - Free Report) by 114.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 238,513 shares of the company's stock after purchasing an additiona
Talaris Therapeutics, Inc. stock logo
Short Interest in Talaris Therapeutics, Inc. (NASDAQ:TALS) Decreases By 71.7%
Talaris Therapeutics, Inc. (NASDAQ:TALS - Get Free Report) was the target of a significant decrease in short interest in June. As of June 30th, there was short interest totalling 270,300 shares, a decrease of 71.7% from the June 15th total of 955,200 shares. Based on an average daily trading volume, of 629,200 shares, the days-to-cover ratio is currently 0.4 days. Currently, 1.3% of the shares of the stock are sold short.
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR
Tourmaline, Talaris Announce All-stock Merger
Talaris Therapeutics, Inc. stock logo
Talaris Therapeutics, Inc. (NASDAQ:TALS) Director Sells $62,530.74 in Stock
Talaris Therapeutics, Inc. (NASDAQ:TALS - Get Rating) Director Suzanne Ildstad sold 25,419 shares of the stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $2.46, for a total value of $62,530.74. Following the sale, the director now owns 3,815,412 shares of the company's stock, valued at approximately $9,385,913.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Talaris Therapeutics, Inc. stock logo
Q2 2023 EPS Estimates for Talaris Therapeutics, Inc. (NASDAQ:TALS) Increased by SVB Leerink
Talaris Therapeutics, Inc. (NASDAQ:TALS - Get Rating) - Investment analysts at SVB Leerink lifted their Q2 2023 earnings per share (EPS) estimates for Talaris Therapeutics in a research report issued on Tuesday, May 16th. SVB Leerink analyst M. Foroohar now anticipates that the company will post
Get Talaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter.

Breaking News: Tesla headed to $500… (Ad)

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address. 

TALS Media Mentions By Week

TALS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TALS
News Sentiment

0.00

0.47

Average
Medical
News Sentiment

TALS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TALS Articles
This Week

0

0

TALS Articles
Average Week

Get Talaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:TALS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners